About: Agalsidase beta

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Agalsidase beta Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Recombinant human alpha-galactosidase A. The mature protein is composed of 2 subunits of 398 residues. Protein is glycosylated and produced by CHO cells (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B4548-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4549-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B454A-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Schaefer RM, Tylki-Szymanska A, Hilz MJ: Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19852524 # El Dib RP, Pastores GM: Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2010 May 12;(5):CD006663. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20464743 # Lim-Melia ER, Kronn DF: Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatr Ann. 2009 Aug;38(8):448-55. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19725195 (en)
http://linked.open...gy/drugbank/group	approved (en) investigational (en)
http://linked.open...drugbank/halfLife	45-102 min (en)
http://linked.open...ugbank/indication	For treatment of Fabry's disease (alpha-galactosidase A deficiency) (en)
sameAs	Agalsidase beta Agalsidase beta
Title	Agalsidase beta (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB00103/identifier/drugbank/DB00103 http://linked.opendata.cz/resource/drugbank/drug/DB00103/identifier/genbank/X14448 http://linked.opendata.cz/resource/drugbank/drug/DB00103/identifier/national-drug-code-directory/58468-0040-1 http://linked.opendata.cz/resource/drugbank/drug/DB00103/identifier/uniprotkb/P06280 http://linked.opendata.cz/resource/drugbank/drug/DB00103/identifier/pharmgkb/PA164746527 http://linked.opendata.cz/resource/drugbank/drug/DB00103/identifier/wikipedia/Agalsidase_beta
http://linked.open...mechanismOfAction	Alpha-galactosidase A catalyzes the hydrolysis of globotriaosylceramide (GL-3) and other a-galactyl-terminated neutral glycosphingolipids, such as galabiosylceramide and blood group B substances to ceramide dihexoside and galactose. (en)
http://linked.open...drugbank/packager	Genzyme Inc. Sandoz
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/2265464
http://linked.open.../drugbank/synonym	Agalsidase alfa (en) Alpha-D- galactoside galactohydrolase (en) Alpha-D-galactosidase A (en) Alpha-galactosidase A precursor (en) Melibiase (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/44-00-00
http://linked.open...y/mesh/hasConcept	http://linked.opendata.cz/resource/mesh/concept/M0430431
foaf:page	http://www.drugs.com/cdi/agalsidase-beta.html http://www.rxlist.com/cgi/generic3/fabrazyme.htm
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B454E-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B454D-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Agalsidase beta
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	104138-64-9 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...rugbank/clearance	* 4.1 +/- 1.2 mL/min/kg [adult patients with Fabry disease,0.3 mg/kg, 1 infusion] * 4.6 +/- 2.2 mL/min/kg [adult patients with Fabry disease, 0.3 mg/kg, 5 infusions] * 2.1 +/- 0.7 mL/min/kg [adult patients with Fabry disease, 1 mg/kg, 1 infusion] * 3.2 +/- 2.6 mL/min/kg [adult patients with Fabry disease, 1 mg/kg, 5 infusions] * 0.8 +/- 0.3 mL/min/kg [adult patients with Fabry disease, 3 mg/kg, 1 infusion] * 0.8 +/- 0.4 mL/min/kg [adult patients with Fabry disease, 3 mg/kg, 5 infusions] * 1.8 +/- 0.8 mL/min/kg [Pediatric Patients with Fabry Disease, 1 mg/kg, 1-3 infusions] * 4.9 +/- 5.6 mL/min/kg [Pediatric Patients with Fabry Disease, 1 mg/kg, 7 infusions] * 2.3 +/- 2.2 mL/min/kg [Pediatric Patients with Fabry Disease, 1 mg/kg, 11 infusions] (en)
http://linked.open...gbank/containedIn	Fabrazyme 5 mg vial Fabrazyme 35 mg vial
http://linked.open...nk/Hydrophobicity	http://linked.opendata.cz/resource/drugbank/property/271B454B-363D-11E5-9242-09173F13E4C5
http://linked.open...Isoelectric-Point	http://linked.opendata.cz/resource/drugbank/property/271B454C-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.116 as of Feb 22 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of Feb 22 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software